Yahoo Web Search

  1. Ads
    related to Merck & Co., Inc
  1. Merck & Co., Inc. (NYSE:MRK) Is An Attractive Dividend Stock, Here's Why

    Simply Wall St. via Yahoo FinanceApr 10 12:52 PM

    The stock currently pays out a dividend yield of 2.7%, and has a market cap of US$209b. In the near future, analysts are predicting lower payout ratio of 39% which, assuming the share price stays the same, leads to a dividend yield of 2.9%.

  2. Merck (MRK) closed the most recent trading day at $80.95, moving -0.25% from the previous trading session. This move lagged the S&P 500's daily gain of 0.11%. Heading into today, shares ...

  3. Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?

    Zacks via Yahoo FinanceApr 25 15:50 PM

    Merck & Co., Inc. MRK will report first-quarter 2019 results on Apr 30 before market open. In the last reported quarter, the company delivered a positive earnings surprise ...

  4. Merck & Co., Inc. MRK announced that the FDA granted approval to its blockbuster anti-PD-1 therapy, Keytruda for an expanded first-line lung cancer indication. It is now ...

  5. Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval

    Zacks via Yahoo FinanceApr 10 14:16 PM

    Amgen, Inc. AMGN and its partner UCB announced that the FDA has approved Evenity (romosozumab-aqqg) for treating osteoporosis in postmenopausal women at high risk of fracture. Evenity ...

  6. NASDAQ: NEO) Adamas Pharmaceuticals Inc (NASDAQ: ADMS) Caladrius Biosciences Inc (NASDAQ: CLBS) Helius Medical Technologies Inc (NASDAQ: HSDT)(FDA declined its request for ...

  7. Vaxart Inc (NASDAQ: VXRT) Teligent Inc (NASDAQ: TLGT) Teva Pharmaceutical Industries Ltd (NYSE: TEVA) Merck & Co., Inc. NYSE: MRK) announced FDA approval for ...

  8. Wall Street slips, weighed down by healthcare plunge

    Reuters via Yahoo FinanceApr 17 20:39 PM

    UnitedHealth Group Inc, Pfizer Inc, Merck & Co Inc and Abbott Laboratories all closed down between 1.9% and 4.7%, and were among the biggest drags on the broader ...

  9. NASDAQ: AEMD) Assembly Biosciences Inc (NASDAQ: ASMB)(presented interim mid-stage results of its hepatitis B virus treatment candidate ABI-H0731) CELLECT BIOTECH/S ADR (NASDAQ: APOP) ...

  10. While Glaxo GSK gained FDA approval for a new two-drug HIV medicine for previously untreated patients, AstraZeneca AZN/Merck's MRK PARP inhibitor, Lynparza was approved for the breast ...

  1. Ads
    related to Merck & Co., Inc